I am a cardiac patient relying on daily blood thinners to stay alive and avoid another medical emergency. Missing a dose or losing access could have serious consequences. That reality makes me pay close attention to proposals that affect medicine availability and future innovation.

Most Favored Nation (MFN) pricing is not the correct path forward. Allowing foreign governments to influence U.S. drug pricing risks limiting access and slowing the development of new treatments. America leads the world in medical innovation because we invest in research, not because we copy systems that restrict it.

If lawmakers want to help patients like me, they should demand transparency in the 340B program. Hospitals benefit from steep drug discounts, yet patients often face high out-of-pocket costs with little explanation. Savings meant to support vulnerable patients should not disappear behind closed doors.

Pennsylvania patients need policies that protect both access and innovation. I hope that Congress will reject MFN-style price-setting and restore accountability to the 340B program so that savings go to patients, which could help ensure the health care system actually works for us—especially those of us who depend on care every day.

Veronica Comfort
Fogelsville, PA